The company's lead product candidate is CABA-201, a fully human anti-CD19 binder for the treatment of Phase 1/2 clinical ...

DelveInsight's 'Lupus Nephritis Pipeline Insight 2024' report provides comprehensive global coverage of pipeline lupus ...

A noninvasive urinary biomarker panel predicts lupus nephritis activity and response better than proteinuria, and, if further validated, may aid diagnosis and gauge treatment response, investigators ...

GLP-1 receptor agonist use is associated with benefits in a number of different disease and may help treat patients with lupus nephritis.

Chicago’s Cour Pharmaceuticals—recently honored as one of Fierce Biotech’s 2024 Fierce 15—is bringing its immunology mission ...

Shares of Aurinia Pharmaceuticals Inc. (TSE:AUP – Get Free Report) (NASDAQ:AUPH) dropped 3.5% during mid-day trading on Monday . The stock traded as low as C$16.41 and last traded at C$16.76.

Washington: During ACR Convergence 2024, the American College of Rheumatology (ACR) unveiled a summary of the 2024 Guideline ...

The U.S. Food and Drug Administration gave SC291, a CD19-directed allogeneic CAR T cell therapy developed using Sana's hypoimmune platform, fast track designation, a process designed to facilitate the ...

Fast Track designation is designed to expedite clinical development and regulatory review timelines Enrolling patients in the GLEAM trial for SC291 in B-cell mediated autoimmune diseases, including ...

which includes extrarenal lupus and lupus nephritis. Fast Track is a process designed to facilitate the development and expedite the review of drugs to treat serious conditions and fill an unmet ...

Unlock your investing potential with TipRanks Premium - Now At 40% OFF!

Manuel Gava, a member of the SPD representing Osnabrück in the Bundestag, has publicly acknowledged his use of cocaine and announced his withdrawal from the electoral race. This revelation comes ...